RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
OBJECTIVES: * Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. * Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Study Type
INTERVENTIONAL
Purpose
SUPPORTIVE_CARE
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.